Last reviewed · How we verify

Supportive care+Tacrolimus+Ripertamab — Competitive Intelligence Brief

Supportive care+Tacrolimus+Ripertamab (Supportive care+Tacrolimus+Ripertamab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody. Area: Oncology.

phase 3 Bispecific antibody T-cell engager (exact targets not fully characterized in public literature) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Supportive care+Tacrolimus+Ripertamab (Supportive care+Tacrolimus+Ripertamab) — Air Force Military Medical University, China. Ripertamab is a bispecific antibody that engages immune cells to target and eliminate cancer cells, combined with supportive care and tacrolimus immunosuppression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Supportive care+Tacrolimus+Ripertamab TARGET Supportive care+Tacrolimus+Ripertamab Air Force Military Medical University, China phase 3 Bispecific antibody T-cell engager (exact targets not fully characterized in public literature)
Elrexfio elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Elrexfio Elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Elrantamab elrantamab Pfizer marketed Bispecific Antibody BCMA (B-cell maturation antigen)
IBI362 IBI362 Innovent Biologics (Suzhou) Co. Ltd. phase 3 Bispecific antibody; PD-1/TGF-β inhibitor PD-1 and TGF-β
AK112, Carboplatin, Paxlitaxel AK112, Carboplatin, Paxlitaxel Akeso phase 3 Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination PD-1 and LAG-3
BAT1706 BAT1706 Bio-Thera Solutions phase 3 Bispecific antibody; PD-1/TGF-β inhibitor PD-1 and TGF-β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody class)

  1. Shanghai Miracogen Inc. · 3 drugs in this class
  2. Atom Therapeutics Co., Ltd · 2 drugs in this class
  3. Pfizer · 2 drugs in this class
  4. Allergan · 1 drug in this class
  5. AstraZeneca · 1 drug in this class
  6. BioNTech SE · 1 drug in this class
  7. DualityBio Inc. · 1 drug in this class
  8. Coherus Oncology, Inc. · 1 drug in this class
  9. Genmab · 1 drug in this class
  10. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Supportive care+Tacrolimus+Ripertamab — Competitive Intelligence Brief. https://druglandscape.com/ci/supportive-care-tacrolimus-ripertamab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: